Articles From: Argex Receives Completed Technical Due Diligence Reports to ARIAD Announces Final Decision from European Commission Endorsing Iclusig’s Approved Indications Throughout Europe


2015/2/17
Argex Receives Completed Technical Due Diligence Reports Canada NewsWire MONTREAL , Feb.
Sign-up for Argex Receives Completed Technical Due Diligence Reports investment picks
2015/2/18
Argex Titanium to Present at the 27th Annual ROTH Conference on March 9, 2015 Canada NewsWire MONTREAL , Feb.
Sign-up for Argex Titanium to Present at the 27th Annual ROTH Conference on March 9, 2015 investment picks
2015/2/17
Argo Group International Holdings, Ltd.
Sign-up for Argo Group Announces a 10% Stock Dividend and an Increase of Its Regular Quarterly Cash Dividend to $0.20 Per Share – a 22.2% Increase from Previous Quarters investment picks
2015/2/3
Argo Group International Holdings, Ltd.
Sign-up for Argo Group CEO to Present at the Bank of America Merrill Lynch Insurance Conference on Feb. 11, 2015; Audio Webcast Available investment picks
2015/2/9
Argo Group International Holdings, Ltd.
Sign-up for Argo Group Reports Record Underwriting Income in 2014 investment picks
2015/1/26
Argo Group International Holdings, Ltd.
Sign-up for Argo Group Schedules Its 2014 Fourth Quarter Earnings Release and Conference Call investment picks
2014/12/16
Argo Group US, Inc., a member of Argo Group International Holdings, Ltd.
Sign-up for Argo Group US, Inc. Acquires Renewal Rights of Lawyers’ Professional Liability Book from OneBeacon investment picks
2015/2/3
Argo Group International Holdings, Ltd.
Sign-up for Argo Insurance Offers New Excess Casualty Facility investment picks
2015/2/20
http://media3.marketwire.com/logos/20120117-argold200.jpg TORONTO, ONTARIO --
Sign-up for Argonaut Gold Confirms Filing of Technical Report and Preliminary Economic Assessment for its San Agustin Project investment picks
2015/1/26
http://media3.marketwire.com/logos/20120117-argold200.jpg TORONTO, ONTARIO --
Sign-up for Argonaut Gold Receives TSX Acceptance of Shareholder Rights Plan investment picks
2015/1/6
DURHAM, N.C. and AURORA, Ohio, Jan.
Sign-up for Argos Therapeutics and Saint-Gobain Announce Agreement for Production of Disposables Used in Automated Manufacturing of Fully Personalized Immunotherapies investment picks
2015/1/23
DURHAM, N.C., Jan.
Sign-up for Argos Therapeutics Chief Operating Officer to Speak at Phacilitate Cell & Gene Therapy Forum 2015 investment picks
2015/1/20
DURHAM, N.C., Jan.
Sign-up for Argos Therapeutics Chief Scientific Officer to Speak at the Personalized Medicine World Conference 2015 investment picks
2015/1/22
DURHAM, N.C., Jan.
Sign-up for Argos Therapeutics Director of Immunology to Speak at the GTCbio Novel Immunotherapeutics Summit 2015 investment picks
2015/1/9
Findings from Phase 2b trial support clinical development of AGS-004 in adult eradication and pediatric studies.
Sign-up for Argos Therapeutics Provides Update on Clinical Research for Investigational Fully Personalized Immunotherapy for the Treatment of HIV investment picks
2015/1/6
DURHAM, N.C., Jan.
Sign-up for Argos Therapeutics to Present at Biotech Showcase 2015 investment picks
2015/2/2
DURHAM, N.C., Feb.
Sign-up for Argos Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference investment picks
2015/3/3
BARCELONA, Spain , March 3, 2015 /PRNewswire/ -- Mobile World Congress - Gigamon ® Inc. (NYSE: GIMO) , the leader in traffic visibility solutions with its innovative Unified Visibility Fabric ™, and Argyle Data , the leader in real-time fraud detection and analytics for data-driven Hadoop organizations in mobile communications and financial services, today announced that the companies are teaming together to deliver fraud detection and revenue protection for communications service providers (CSPs). According to the Communications Fraud Control Association's 2013 Global Fraud Loss Survey , an estimated $46.3 billion annually is lost to fraud, and fraud losses are "growing at a faster pace than global telecom revenues." The high priority fraud types and methods that cost most to CSPs include roaming fraud, subscription fraud, PBX hacking, VoIP hacking and Wangiri fraud.
Sign-up for Argyle Data and Gigamon to Deliver Real-Time Fraud Detection and Analytics for Communications Service Providers investment picks
2014/12/9
MILWAUKEE, Dec.
Sign-up for ARI and Shopatron Partner to Deliver Unified eCommerce Solution investment picks
2014/12/11
MILWAUKEE, Dec.
Sign-up for ARI Network Services Announces Fiscal 2015 First Quarter Results investment picks
2015/2/23
MILWAUKEE, Feb.
Sign-up for ARI Network Services, Inc. to Present at the 27th Annual ROTH Conference investment picks
2015/2/16
MILWAUKEE, Feb.
Sign-up for ARI Partners With ChannelAdvisor to Offer Powersports Dealers Multi-Channel, eCommerce Solution investment picks
2014/12/18
MILWAUKEE, Dec.
Sign-up for ARI to Hold Annual Shareholder Meeting January 6, 2015 investment picks
2015/1/30
SACO, Maine and NOVI, Mich., Jan.
Sign-up for Aria Energy and Casella Waste Systems to Develop Renewable Energy Project at Juniper Ridge Landfill investment picks
2014/12/23
ARIAD Pharmaceuticals, Inc. (ARIAD; NASDAQ: ARIA) and Otsuka Pharmaceutical Co., Ltd.
Sign-up for ARIAD and Otsuka Announce Co-Development and Commercialization Agreement for Iclusig to Treat Leukemias in Japan and Nine Other Asian Countries investment picks
2015/1/22
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Thomas J.
Sign-up for ARIAD Announces Appointment of Thomas J. DesRosier, Senior Pharmaceutical-Industry Counsel, as Chief Legal and Administrative Officer investment picks
2014/12/30
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Angelini Pharma, through the Austrian subsidiary CSC Pharmaceuticals, today announced that ARIAD has granted Angelini exclusive rights to commercialize Iclusig ® (ponatinib) for the indications approved by the European Medicine Agency (EMA) in Central and Eastern Europe.
Sign-up for ARIAD Announces Commercialization Agreement for Iclusig in Seven Central and Eastern European Countries investment picks
2015/1/20
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the European Commission (EC) has endorsed the final opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) on Iclusig ® (ponatinib) following recommendations made by the Pharmacovigilance Risk Assessment Committee (PRAC). This concludes the European Article 20 review of Iclusig and is a binding decision for Iclusig to continue to be prescribed in Europe in accordance with its already approved indications.
Sign-up for ARIAD Announces Final Decision from European Commission Endorsing Iclusig’s Approved Indications Throughout Europe investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Argex Receives Completed Technical Due Diligence Reports to ARIAD Announces Final Decision from European Commission Endorsing Iclusig’s Approved Indications Throughout Europe
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent